Sensorion S.A.

ALSEN.PA

Biotechnology · Healthcare

Exchange

Euronext Paris

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Sensorion is a French biotech company focused on treating hearing loss and inner ear disorders. It develops gene therapies and drug treatments aimed at people who are deaf or hard of hearing, including patients with genetic forms of hearing loss. The company does not yet sell approved products — it is in the clinical trial stage, testing its therapies in human studies.

Sensorion earns very little revenue today, which explains its deeply negative operating margin. It is funded mainly through grants, partnerships, and capital raises rather than product sales. Based in Montpellier, France, it operates primarily in Europe but runs trials with international reach. Its focus on gene therapy for the inner ear is a specialized niche with few direct competitors, but the main risk is significant: the company must successfully complete clinical trials and gain regulatory approval before it can generate meaningful revenue, and failure at any trial stage could threaten its survival.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-9.9% YoY

YoY Growth Rate

Earnings declining

Insider Activity

13.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~17 months

€48M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Sensorion S.A.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-80.7%

Weak — -80.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-65.0%

Shrinking sales (-65.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-1187.9%

Burning cash (-1187.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.02

Conservative — low debt load (0.02)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial